ERBB2 and ovarian carcinoma: Our pre-clinical data show that the CAM1615HER2 TriKE induces activity against HER2-expressing tumors, activates NK cells via CD16 resulting in specific killing of ovarian cancer spheroids, drives specific NK cell expansion, and induces control of the ovarian tumor in vivo.